Company Overview and News
Price controls have resulted in new homes being sold at 20-30pc discounts, which has had the knock-on effect that developers are reluctant to sell
Stocks in China and Hong Kong rallied on Wednesday, led by real estate firms, after developers posted stellar profits for 2017.
Mainland property developers have posted strong earnings for 2017, but liquidity remains a concern as Beijing keeps a tight lid on financing to cool the housing market.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Increased profitability and market share are behind the possible gains for companies like China Vanke and Evergrande, even though overall sales could fall, the investment bank says
After the rebalancing, the weighting of China’s new-economy companies is likely to make up 28 per cent of the H-share index, up from 6 per cent currently, according to China International Capital Corp
China stocks rose on Monday morning to new two-year highs, helped by gains in the defensive consumer and healthcare firms as well as a boost from tech shares.
The Hang Seng Index posts its best weekly gain since October, while Shanghai shares record their biggest weekly jump in more than a year
Fearless acquisition strategy by company’s chairman Huang Qisen has sparked both fear and admiration among industry peers. But its shares have rallied 53pc in the past month despite heightened concern over its debt ratio and cash flow
Flats to be built on land at Wong Chuk Hang are likely to fetch prices similar to those in the city’s more traditional upmarket areas, analysts forecast
A plot of residential land for sale by tender in the south of Hong Kong Island may be the latest proof that local developers are close to regaining the upper hand in the competition for space to build their projects.
Happy Mid-Autumn Festival. China is on holiday until October 9 so the newsletter is very sporadic this week. There may be one more issue by the end of the weekend, then back to normal publishing next week.
Happy Wednesday…A bit under the weather here in DC, pardon any typos. If you are in Beijing have fun with the evening rush hour over the next few days. The city is warning that they will be epic…
The real estate sector is beginning to show signs of coming out of its recent downturn as persistently low mortgage rates, an improving world economy, and domestic reconstruction efforts in both Texas and Florida are acting as the catalysts for the sector. On the domestic side, the Federal Housing Finance agency recently reported that mortgage rates for newly built homes was up just 7 basis points in August to +4.
President Trump announced an executive order Thursday to grant additional authority to the Treasury Department to enforce economic sanctions on North Korea and foreign companies and individuals that do business with the rogue nation in Northeast Asia.
2018-05-19 - Asif
OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...
2018-05-19 - Asif
Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...
2018-05-17 - Asif
Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...